Karus Therapeutics presenting at the CHI DoT 11th Annual Next-Generation Histone Deacetylase Inhibitors conference

Oxford, UK, 4 August 2017 – Karus Therapeutics Ltd, a leader in the development of innovative medicines for the treatment of cancer, has announced its COO/CSO will be delivering two presentations at the CHI DoT 11th Annual Kinase Inhibitor Discovery conference, Boston, 27 and 28 September 2017.

The presentation on Wednesday 27 September by Stephen Shuttleworth, COO & CSO, entitled Design and Development of a Novel, Selective PI3K-p110β/δ Inhibitor, KA2237, for the Treatment of Cancer will take place at 5:00pm.

In addition, on Thursday 28 September 2017, Dr. Stephen Shuttleworth will deliver a second presentation entitled Design and Development of KA2507, an Orally-Active HDAC6-Selective Inhibitor with Tumor Immunotherapeutic Activity at 11:50am.

For more information on Karus’s presentations or for media enquiries, please contact karus@instinctif.com.